Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical BM-MSCs for Recessive Dystrophic Epidermolysis Bullosa
NCT04153630Phase 2Unknown
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- May 2018
- Primary completion
- Mar 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bone marrow-derived mesenchymal stem cells in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Hospital La Paz Institute for Health Research. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 year. Status: unknown.
02
Drugs
bone marrow-derived mesenchymal stem cells
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT04153630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153630.